Pfizer released a better than expected second-quarter earnings report and increased its guidance before the markets opened on Tuesday.
Pfizer and BioNTech made another big step in their fight against COVID-19 by initiating their late-stage study for their lead mRNA vaccine candidate.
MediciNova saw the coronavirus bump on Monday after it said it had entered a worldwide exclusive agreement with BioComo for the rights to develop a SARS-CoV-2 vaccine.
The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Arbutus Biopharma stock has seen an incredible rise over the past few days after the firm won a patent dispute that could have implications for coronavirus vaccine frontrunner Moderna.
Goldman Sachs has seven biopharma stocks on its Conviction Buy list, and these are not all coronavirus plays. The firm thinks these stocks could go on the offensive for the rest of the year.
Milestone Pharmaceuticals shares more than doubled on Thursday after the company announced a key clinical and regulatory update.
Pfizer and BioNTech S.E. aim to begin delivering 300 million doses of their vaccine for COVID-19 in 2021, but in the meantime, these companies will get a nice payoff.
BioNTech is one of the leading companies in the race to a COVID-19 vaccine. With its shares up more than 160% year to date, it’s time to capitalize.
Lexicon Pharmaceuticals shares surged on Tuesday after the company announced positive topline data for its late-stage studies in type 2 diabetes.
Moleculin Biotech joins the ever-expanding list of coronavirus stocks as the company announced that a second round of independent laboratory testing has confirmed the antiviral activity of WP1122.
Immuron continued its winning streak on Tuesday after the company announced that its IMM-124E has demonstrated neutralizing activity against the severe acute respiratory syndrome due to the virus...
Sorrento Therapeutics has announced that its treatment for COVID-19 had cleared its Phase 2 study in hospitalized patients with moderate to severe coronavirus infections.
GlaxoSmithKline has announced that it is acquiring a 10% stake in the German biopharma firm CureVac.